Retagliptin

Retagliptin

Retagliptin is an antidiabetic drug used in the treatment of type 2 diabetes. It belongs to the class of drugs known as dipeptidyl peptidase-4 inhibitors or DPP-4 inhibitors.

Mechanism of Action

Retagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme is responsible for the breakdown of incretin hormones, which are released by the intestines in response to food intake. By inhibiting DPP-4, Retagliptin increases the levels of incretin hormones in the body. These hormones stimulate the release of insulin from the pancreas, reduce the production of glucose by the liver, and slow down the rate at which the stomach empties after eating. All these actions help to control blood glucose levels.

Uses

Retagliptin is used in the management of type 2 diabetes. It is often used in combination with other antidiabetic drugs such as metformin or a sulfonylurea when monotherapy with these drugs is not sufficient to control blood glucose levels.

Side Effects

Common side effects of Retagliptin include nausea, vomiting, diarrhea, and abdominal pain. Rare but serious side effects can include pancreatitis and severe hypoglycemia.

Contraindications

Retagliptin is contraindicated in patients with a history of hypersensitivity to the drug or any of its components. It is also contraindicated in patients with type 1 diabetes or diabetic ketoacidosis as it is not effective in these conditions.

Drug Interactions

Retagliptin may interact with other drugs including ketoconazole, rifampin, and digoxin. Therefore, it is important to inform the healthcare provider of all medications being taken before starting treatment with Retagliptin.

See Also

• Dipeptidyl peptidase-4 inhibitors
• Type 2 diabetes
• Incretin